top of page
Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors!
Dracen Pharmaceuticals, Inc. has announced the start of a clinical trial of DRP-104, an anti-cancer substance developed by the team of Pavel Majer at IOCB Prague in collaboration with Johns Hopkins University in Baltimore (USA) @johnshopkinsu . The first patients have received the substance, and the initial phase of the trial will last approximately three years.
bottom of page